GALTMEDIUM SIGNALFINANCIAL10-K

GALT significantly reduced operating losses and R&D spending while restructuring liabilities, but accumulated deficit deepened and total debt burden increased.

The company appears to be in a cost-cutting phase, slashing R&D expenses by 61% and improving operating cash flow burn by 43%, suggesting either strategic pivoting or financial preservation measures. However, the 21% increase in total liabilities coupled with deepening stockholders' deficit indicates ongoing financial strain that requires monitoring.

Comparing 2026-03-31 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

GALT demonstrated mixed financial performance with significant improvements in operational efficiency - operating losses decreased 53% and R&D expenses fell 61% - while maintaining slightly higher cash reserves. However, the company's financial position deteriorated with stockholders' equity falling deeper into deficit by 22% and total liabilities increasing 21%, suggesting ongoing capital structure challenges. The dramatic 77% reduction in current liabilities paired with higher long-term debt indicates a liability restructuring that may have provided near-term breathing room but at the cost of increased future obligations.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+170.3%
$1.0M$2.8M

Interest expense surged 170.3% — significant debt increase or rising rates materially impacting earnings.

Current Liabilities
Balance Sheet
-77.3%
$35.4M$8.0M

Current liabilities reduced — improved short-term financial position and working capital health.

R&D Expense
P&L
-60.9%
$36.6M$14.3M

R&D spending cut 60.9% — could signal cost discipline or concerning reduction in innovation investment.

Operating Income
P&L
+52.7%
-$42.4M-$20.1M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Operating Cash Flow
Cash Flow
+42.8%
-$41.8M-$23.9M

Operating cash flow surged 42.8% — exceptional cash generation, highest quality earnings signal.

Net Income
P&L
+34.5%
-$47.0M-$30.8M

Net income grew 34.5% — bottom-line growth signals improving overall business health.

Stockholders Equity
Balance Sheet
-22.1%
-$104.8M-$127.9M

Equity decreased 22.1% — buybacks or losses reducing book value, monitor solvency ratios.

Total Liabilities
Balance Sheet
+20.9%
$120.6M$145.7M

Liabilities increased 20.9% — monitor debt-to-equity ratio and interest coverage.

Cash & Equivalents
Balance Sheet
+17.2%
$15.1M$17.7M

Cash grew 17.2% — improving liquidity position supports investment and shareholder returns.

Current Assets
Balance Sheet
+12.7%
$17.3M$19.4M

Current assets grew 12.7% — improving short-term liquidity or inventory/receivables build.

LANGUAGE CHANGES
NEW — 2026-03-31
PRIOR — 2025-03-31
ADDED
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.
1 INDEX TO FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2025 PAGE PART 1 ITEM 1.
Exhibits and Financial Statement Schedules 76 ITEM 16 Form 10-K Summary 80 SIGNATURES 81 1 Index PART I Item 1.
We focus on diseases with serious, life-threatening consequences and those where current treatment options are limited specifically in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis and certain cancer indications.
1 Index Belapectin demonstrated consistent, meaningful effects across multiple key biomarkers in MASH cirrhosis.
+7 more — sign up free →
REMOVED
Exhibits and Financial Statement Schedules 43 ITEM 16 Form 10-K Summary 46 SIGNATURES 47 Index PART I Item 1.
We focus on diseases with serious, life-threatening consequences and those where current treatment options are limited specifically in NASH (non-alcoholic steatohepatitis) with cirrhosis and certain cancer indications.
The Company continues to analyze trial data and expects to report additional information on specific biomarkers in the second quarter of 2025.
The Company continues to analyze data from approximately 55 patients that completed 36 months of treatment prior to the ending of the trial in February 2025.
While data from this group would not change the results of the NAVIGATE clinical trial for patients completing 18 months of treatment, the Company believes that any encouraging results from this group of patients may draw interest from potential strategic partners.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →